Discussion Forums > Working Towards a Cure

Bluebird Bio Releases Data on Current Gene Therapy Trials

<< < (9/39) > >>

Andy Battaglia:
And for those keeping track, Bluebird's stock rose more than $4/share today.

Parin:
Bluebird Bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are Transfusion-Free

http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=1995913


Regards,
Ashutosh

Sharmin:
This news is beyond incredible Andy.  For Beta zero patients - I am assuming we would be looking at patient 1106 and 1107 for the next few months.  It is impressive that their hemoglobins are 9.6 are 3 months and 1 month.   Even if the hemoglobin were to stay at this level it is remarkable success. 

Hoping this works for everyone!

It would be nice to see follow up data regarding any possible deficits due to bisulfan - such as fertility.  But that is a future consideration.  for the time being - this is life changing!

Sharmin

Andy Battaglia:
Bluebird's stock value has doubled today.

Andy Battaglia:
I should be having another phone conference with Bluebird later this week. If there are any questions you would like asked, please reply by Thursday morning at the latest.

Navigation

[0] Message Index

[#] Next page

[*] Previous page